TransMedics Group, Inc. (NASDAQ:TMDX) Shares Sold by Oak Ridge Investments LLC

Oak Ridge Investments LLC decreased its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 2.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,327 shares of the company’s stock after selling 488 shares during the quarter. Oak Ridge Investments LLC’s holdings in TransMedics Group were worth $2,720,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TMDX. Fidelis Capital Partners LLC acquired a new stake in TransMedics Group during the 1st quarter worth about $35,000. International Assets Investment Management LLC acquired a new stake in TransMedics Group during the 2nd quarter worth about $47,000. USA Financial Formulas acquired a new stake in TransMedics Group during the 3rd quarter worth about $55,000. J.Safra Asset Management Corp lifted its position in TransMedics Group by 649.2% during the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock worth $67,000 after acquiring an additional 383 shares during the period. Finally, Signaturefd LLC lifted its position in TransMedics Group by 26.6% during the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after acquiring an additional 93 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

Insider Activity at TransMedics Group

In other TransMedics Group news, Director Edward M. Basile sold 6,750 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $149.96, for a total transaction of $1,012,230.00. Following the completion of the sale, the director now directly owns 732 shares in the company, valued at approximately $109,770.72. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other TransMedics Group news, Director Edward M. Basile sold 6,750 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $149.96, for a total transaction of $1,012,230.00. Following the completion of the sale, the director now directly owns 732 shares in the company, valued at approximately $109,770.72. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Tamer I. Khayal sold 2,958 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total value of $438,493.92. Following the sale, the insider now owns 20,843 shares of the company’s stock, valued at approximately $3,089,766.32. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 61,247 shares of company stock worth $9,518,181 in the last 90 days. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Price Performance

Shares of TransMedics Group stock opened at $81.97 on Friday. The company has a quick ratio of 8.48, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a twelve month low of $36.42 and a twelve month high of $177.37. The business has a 50-day moving average price of $142.38 and a 200 day moving average price of $139.36. The firm has a market cap of $2.75 billion, a PE ratio of 87.20 and a beta of 1.99.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The business had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. During the same quarter in the prior year, the firm earned ($0.12) EPS. TransMedics Group’s revenue for the quarter was up 63.7% on a year-over-year basis. Sell-side analysts predict that TransMedics Group, Inc. will post 1.11 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have commented on TMDX shares. Canaccord Genuity Group lowered their price target on TransMedics Group from $169.00 to $109.00 and set a “buy” rating for the company in a research report on Tuesday. Piper Sandler reissued an “overweight” rating and issued a $180.00 price objective on shares of TransMedics Group in a report on Tuesday. Needham & Company LLC decreased their price objective on TransMedics Group from $208.00 to $109.00 and set a “buy” rating for the company in a report on Tuesday. Stephens boosted their price objective on TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Finally, JPMorgan Chase & Co. decreased their price objective on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a report on Tuesday. One analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $144.80.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.